Clinical updates, including trial initiations, enrollment status and data readouts and publications: Codagenix, Crinetics, Endeavor, Harbour, Junshi, Karyopharm, Obseva, Osivax, Pharmazz.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antios, Assembly, Astrazeneca, Bavarian Nordic, Citius, Teva.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aerie, Alnylam, Alvotech, Caladrius, Cingulate, Cytokinetics, Edesa, Eli Lilly, Ensysce, Luxa, Pfizer, Recardio, Springworks, Windtree.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Altamira, Astrazeneca, Bharat, Biohaven, Depymed, Eiger, Greenwich, Immunitybio, Immunogen, Nymox, Ocugen, Regeneron, Salubris, Sanofi, Therapeuticsmd.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antares, Benevira, Biomx, Blade, CASI, Clearmind, Dongcheng, Galapagos, Genocea, Halozyme, Insilico, Imaginab, Journey, Kalivir, Knight, Padagis, Rigel, Roche, RS, Scipher, Scisparc, Synthonics, Sparrow, Tianshi, ZZ.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Alnylam, Antengene, Armata, Aurinia, Biond, Chinook, Compass, Concert, Day One, Hansa, Idorsia, Janssen, Liminal, Neurocrine, Pfizer, Polypid, Rapt, Regeneron, Salubris, Saniona, Seagen, Stealth, Tenax, Teva, UCB, Visen.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alcon, Aptamer, Cantargia, Catalyst, Elicio, Entasis, Immunocore, Immunome, Innoviva, Kala, Lupagen, Medison, Mirum, Pharmacyte, Pinotbio, Quoin, Satiogen, St. Jude, Umoja and Vertex.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Aldeyra, Argenx, Athersys, Avalo, Axsome, Belief, Bridgebio, Enanta, Foghorn, Healios, Insmed, IO Biotech, Lipidor, Menarini, Lysogene, Mustang, Ocuphire, Qlaris, Radius, Recce, Regencell, Rocket, Scilex, Tricida, Ultragenyx, Zealand.

After listing on the Nasdaq market on May 18, Hong Kong-based diagnostics and genetic testing company Prenetics Group Ltd. saw its shares fall nearly 30% in early trading, dropping from $8.40 per share on listing to $5.70 by the end of trading May 19. Trading under the ticker PRE, Prenetics formed a merger with Artisan Acquisition Corp., a special purpose acquisition company, which was founded by entrepreneur Adrian Cheng. The transaction values Prenetics at an enterprise value of $1.25 billion, making the company the first Hong Kong unicorn to list on the Nasdaq.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Anika, Nanomix, Trinity Biotech.